Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Servier Collaborates in The Treatment of Pancreatic Cancer
Details : Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program®) will be responsible for clinical research activities. Servier will fund the associated research costs. The target identification program will be funded by OPM and Servier...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 22, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : SEngine Precision Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : SEngine and Oncodesign have initiated a joint research collaboration to evaluate the feasibility to convert the already identified Nanocyclix® inhibitor series into drug candidates that are likely to be effective in the clinic.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : SEngine Precision Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nanocyclix Drug Candidates
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Recipient : Tiumbio
Deal Size : Undisclosed
Deal Type : Collaboration
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
Details : Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy ...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 21, 2021
Lead Product(s) : Nanocyclix Drug Candidates
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Recipient : Tiumbio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Servier
Deal Size : $363.3 million
Deal Type : Partnership
Oncodesign and Servier Reach a Key First Milestone
Details : The partnership drew on the complementary expertise of Servier and Oncodesign in the fields of neurodegenerative diseases and macrocyclic kinase inhibitors.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $3.3 million
February 17, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Servier
Deal Size : $363.3 million
Deal Type : Partnership
LOOKING FOR A SUPPLIER?